DrugPatentWatch Database Preview
Details for Patent: 10,471,067
Email this page to a colleague
» See Plans and PricingWhich drugs does patent 10,471,067 protect, and when does it expire?
Patent 10,471,067 protects ANJESO and is included in one NDA.
This patent has seventeen patent family members in nine countries.
Summary for Patent: 10,471,067
| Title: | Nanoparticulate meloxicam formulations |
| Abstract: | The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm. |
| Inventor(s): | Cooper; Eugene R. (Berwyn, PA), Ryde; Tuula (Malvern, PA), Pruitt; John (Suwanee, GA), Kline; Laura (Harleysville, PA) |
| Assignee: | Recro Pharma, Inc. (Malvern, PA) |
| Application Number: | 15/437,534 |
|
Patent Claim Types: see list of patent claims | Use; Compound; Dosage form; |
Recent additions to Drugs Protected by US Patent 10,471,067
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baudax | ANJESO | meloxicam | SOLUTION | 210583 | Feb 20, 2020 | RX | Yes | Start Trial | Y | Start Trial | U-2750 | MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,471,067
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,471,067
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 431131 | Start Trial | |||
| Canada | 2517679 | Start Trial | |||
| Germany | 602004021107 | Start Trial | |||
| Denmark | 3090731 | Start Trial | |||
| European Patent Office | 1617816 | Start Trial | |||
| European Patent Office | 1938803 | Start Trial | |||
| European Patent Office | 3090731 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
